Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Cystic Fibrosis: KOL Insight [2017]

Product Code:
Publication Date:
February 2017

How will the novel CFTR-function restoring therapies impact the CF landscape?

The arrival of Vertex’s Kalydeco and Orkambi was a major advance in the disease-modifying CF therapy. However, despite their comparative success, patients’ progress and demand persists for improved modalities that can restore the CFTR function in all CF genotypes. Vertex’s tezacaftor + ivacaftor and Galapagos NV/AbbVie’s GLPG 1837 form part of a rich pipeline, but which candidates stand out to key opinion leaders (KOLs)? Which products and combinations are likely to succeed? And will they improve survival and help patients live beyond their current life expectancy of ~40 years?

Learn how KOLs see the CF market evolving in KOL Insight: Cystic Fibrosis (CF).

12 US and European KOLs provide candid insights on 4 marketed and 11 emerging therapies targeting CFTR function and symptomatic aspects of the CF disease.

Download sample pages

Plus: Order the report and you’ll receive three quarterly FirstWord Therapy Trends Update Bulletins free!

Top Takeaways

  • Can Vertex’ Kalydeco (ivacaftor) maintain its leading position in the CF market? Galapagos NV and AbbVie are developing GLPG 1837, a potentiator which also targets F508del and G551D? Find out how GLPG 1837 and other competitors stack up to ivacaftor?
  • Will Orkambi (ivacaftor/lumacaftor) gain wider acceptance in the market? There is considerable pushback from payers and insurance programmes on the pricing of CF therapies. What do KOLs think about the drug’s prospects and what factors can its uptake in CF patients?
  • Is there a future for PTC Therapeutics’ Translarna? The drug is already approved for to treat patients with nonsense mutation Duchenne muscular dystrophy (nmDMD) but will the drug reach the CF market?
  • Will Vertex’s follow-up small molecule tezacaftor replace lumacaftor in Orkambi in the near future? How do KOLs compare its safety and efficacy and will patients have adequate access to the tezacaftor + ivacaftor combination?
  • Triple combination therapy with CFTR modulators is on the horizon. What impact are they likely to have and which ones will succeed? Vertex's is leading the race with tezacaftor and its next-generation (VX-152 and VX-440) corrector molecules with Galapagus/AbbVie's hot on its heels with its CFTR modulators (GLPG1837 and GLPG2222). Find out how KOLs weigh up these new drug options.
  • Will Genentech/Roche's Pulmozyme remain ingrained in the CF treatment pathway? Or is it likely to be superseded by emerging candidates such as AIR DNase (alidornase alfa; Protalix BioTherapeutics), inhaled OligoG (AlgiPharma) and Parion/Vertex's VX-371.
  • How do KOLs view the development of anti-inflammatory drugs for CF? There are no approved drugs for CF in this class but what concerns do these experts have about drugs targeting leukotriene A4 hydrolase (LTA4H) and cannabinoid receptor CB2 pathways? How do they see their long-term potential?
Request sample pages

Back to the top


“It is very rare that you see a treatment in any condition, particularly in respiratory medicine, where there is a very clear ‘treatment makes you better, stopping it makes you worse’. You know, utterly transformative in the way that ivacaftor was for those patients.”
EU Key Opinion Leader

Sample of therapies covered

Marketed Therapies

  • Kalydeco (ivacaftor; Vertex)
  • Orkambi (lumacaftor/ivacaftor; Vertex)
  • Pulmozyme (dornase alfa; Genentech/Roche )
  • Bronchitol (inhaled mannitol; Pharmaxis)

Pipeline Therapies

  • Riociguat (Bayer)
  • GLPG1837 (Galapagos/AbbVie)
  • Translarna (ataluren; PTC Therapeutics)
  • Tezacaftor (VX-661) + ivacaftor (Vertex)
  • VX-371 (formerly P-1037; Parion Sciences/Vertex)
  • Acebilustat (CTX-4430; Celtaxsys/CFF Therapeutics)
  • Plus 5 more - download the full list now >

Sample of KOLs interviewed

KOLs from North America

  • Dr Patrick Flume, MD, Powers-Huggins Endowed Chair for Cystic Fibrosis, Professor of Medicine and Pediatrics, Medical University of South Carolina, Charleston, SC, USA.
  • Dr Michael W. Konstan, MD, Vice Dean for Translational Research, Professor of Pediatrics at Case Western Reserve University School of Medicine, Cleveland, OH, USA.
  • Dr Richard B. Moss, MD, Emeritus Professor of Pediatrics and former chief of the Pediatric Pulmonary and Allergy Divisions, Stanford University, Palo Alto, CA, USA.

KOLs from Europe

  • Dr Carla Colombo, MD, Professor of Paediatrics, Department of Paediatrics, University of Milan, Italy.
  • Professor Stuart Elborn, MD, FRCP, CBE, Former president of the European Cystic Fibrosis Society. Professor of Respiratory Medicine and Dean of the School of Medicine, Dentistry and Biomedical Sciences at Queen’s University, Belfast, UK.
  • Dr Harry G.M. Heijerman, MD, Director of the Adult CF Centre, Hague Teaching Hospital, The Hague, Netherlands.

Plus 6 more - download the full list now >

Money Back Guarantee

At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.

Ongoing Benefits

The world of pharma is ever changing and executives must always be up-to-date with new developments that could affect their own products, position and research. That is why FirstWord's guarantee to keep Therapy Trends clients up to date with Update Bulletins offers a real commercial advantage.

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.

  • Your Therapy Trends Report purchase entitles you to receive three Update Bulletins, which are published approximately every three months for 12 months following the report's publication date.
  • You will receive a copy of each Update Bulletin once available, which are issued each quarter after the publication date.


All Contents Copyright © 2020 Doctor's Guide Publishing Limited All Rights Reserved